RESUMO
Immunosuppressive therapy is a therapeutic option for selected low-risk myelodysplastic syndromes (MDS) patients. Besides standard treatment protocols that include ATG and CSA, the humanized CD52 antibody alemtuzumab has been shown to have efficacy in MDS treatment. We report our experience with alemtuzumab in nine MDS RCMD patients. All patients had a hypocellular bone marrow with a blast count <5 % and were classified as intermediate-1 according to the IPSS. We found a response in five patients (60 %); three patients achieved a complete remission 3 and 6 months after the treatment with alemtuzumab, and two patients showed a haematological improvement. Alemtuzumab was administered in a 10-mg dosage for 10 days. Treatment was well tolerated, and no severe side effects were observed. We could confirm the finding that the alemtuzumab is effective and save selected MDS patients. Due to the promising results, further studies, especially with regard to long-term survival and risk of leucemic progression should be initiated.
Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Medula Óssea/patologia , Imunossupressores/uso terapêutico , Síndromes Mielodisplásicas/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Alemtuzumab , Anticorpos Monoclonais Humanizados/administração & dosagem , Anticorpos Monoclonais Humanizados/efeitos adversos , Antígenos CD/imunologia , Antígenos de Neoplasias/imunologia , Transfusão de Componentes Sanguíneos , Antígeno CD52 , Contagem de Células , Terapia Combinada , DNA (Citosina-5-)-Metiltransferases/genética , DNA Metiltransferase 3A , Avaliação de Medicamentos , Feminino , Glicoproteínas/antagonistas & inibidores , Glicoproteínas/imunologia , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/efeitos adversos , Injeções Intravenosas , Injeções Subcutâneas , Masculino , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/genética , Síndromes Mielodisplásicas/patologia , Síndromes Mielodisplásicas/terapia , Indução de Remissão , Estudos RetrospectivosRESUMO
PURPOSE: This study aimed to prove the usefulness of the diagnostic plot, using the haemoglobin content of reticulocytes as a measure of functional iron deficiency (FID) and the ferritin index as a measure of iron availability, to customise anaemia treatment in cancer patients. METHODS: Based on results of this plot, cancer patients fulfilling practice guideline criteria to receive erythropoiesis-stimulating agents (ESAs) were allocated to treatment with ESAs alone, iron alone or the combination of both. Primary endpoint was the percentage of patients identified to require iron in addition or as an alternative to ESA therapy. RESULTS: Out of 303 patients screened, 286 were allocated to treatment: 204 patients were normochromic and iron replete and treated with ESAs alone, 22 had both FID and anaemia of chronic disease and were treated with ESAs and parenteral iron, and 60 were iron-depleted and treated with iron only. After 8 weeks, a haemoglobin increase >1 g/dL from baseline was shown by 56% of patients treated with ESAs alone, by 100% of patients receiving the combination, by 50% of normochromic and by 73% of hypochromic iron-depleted patients receiving iron only. Acute phase reaction did not diminish the response rate to ESAs. CONCLUSIONS: The diagnostic plot was superior to transferrin saturation and ferritin in predicting iron availability in hypochromic patients treated with ESAs and proved useful to select treatment for anaemia in cancer patients.
Assuntos
Anemia/diagnóstico , Anemia/tratamento farmacológico , Hematínicos/uso terapêutico , Hemoglobinas/metabolismo , Neoplasias/sangue , Anemia/sangue , Anemia/etiologia , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Biomarcadores/sangue , Diagnóstico Diferencial , Feminino , Ferritinas/sangue , Ferritinas/deficiência , Hematínicos/efeitos adversos , Hemoglobinas/deficiência , Humanos , Ferro/administração & dosagem , Ferro/sangue , Deficiências de Ferro , Masculino , Pessoa de Meia-Idade , Neoplasias/tratamento farmacológico , Guias de Prática Clínica como Assunto , Estudos Prospectivos , Reticulócitos/metabolismoRESUMO
This is a report about a patient who had a complete remission of a metastatic pancreatic adenocarcinoma after a modified G-FLIP therapy administered in an outpatient setting. The patient underwent surgery and the complete remission could be proven histologically. The administered chemotherapy was very effective and is even more attractive since it could be administered without admission to hospital.
Assuntos
Antineoplásicos/uso terapêutico , Metástase Neoplásica/tratamento farmacológico , Neoplasias Pancreáticas/tratamento farmacológico , Neoplasias Pancreáticas/patologia , Idoso , Antineoplásicos/efeitos adversos , Quimioterapia Combinada , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Feminino , Humanos , Metástase Neoplásica/patologia , Recidiva , Fatores de Tempo , Tomógrafos ComputadorizadosAssuntos
Neoplasias dos Ductos Biliares/genética , Biomarcadores Tumorais/genética , Colangiocarcinoma/genética , Predisposição Genética para Doença/genética , Isocitrato Desidrogenase/genética , Proteínas de Neoplasias/genética , Neoplasias dos Ductos Biliares/diagnóstico , Colangiocarcinoma/diagnóstico , HumanosRESUMO
OBJECTIVE: Treatment with erythropoiesis-stimulating factors (ESFs) can ameliorate anemia associated with cancer and chemotherapy. However, half of anemic cancer patients do not respond even to high doses. To determine factors that are predictive of a treatment response, a multicenter, prospective study was performed. PATIENTS AND METHODS: Investigated factors were baseline erythropoietin, reticulocytes and soluble transferrin receptor (sTfR) after 2 weeks, and reticulocytes and hemoglobin after 4 weeks. Anemic patients with solid tumors received 150 microg/week of darbepoetin concomitantly with chemotherapy. The dose was doubled if hemoglobin did not increase by >1 g/dl after 4 weeks. Patients were considered responders if hemoglobin increased by >or=2 g/dl or reached a level >or=12 g/dl within 8-12 weeks. RESULTS: In total, 196 patients were enrolled; 61% of the intention-to-treat (ITT) and 68% of the per-protocol population were responders. In the ITT population, the hemoglobin increase after 4 weeks indicated an 11-fold higher chance of response (odds ratio, 11.0; 95% confidence interval [CI], 5.1-23.6; sensitivity, 88%; specificity, 60%). In a multiple logistic regression model including all factors, the area under the receiver operating characteristic curve was 0.78 (95% CI, 0.71-0.84). The combination of sTfR after 2 weeks and hemoglobin after 4 weeks was as predictive as the combination of all five tested factors. CONCLUSION: So far, an early hemoglobin increase remains the single most predictive factor for response to ESF treatment. In contrast to anemic patients with lymphoproliferative malignancies, serum erythropoietin had little predictive value in patients with solid tumors.